CCAAT-Enhancer-Binding Protein-alpha

A CCAAT-enhancer-binding protein found in LIVER; ADIPOSE TISSUE; INTESTINES; LUNG; ADRENAL GLANDS; PLACENTA; OVARY and peripheral blood mononuclear cells (LEUKOCYTES, MONONUCLEAR). Experiments with knock-out mice have demonstrated that CCAAT-enhancer binding protein-alpha is essential for the functioning and differentiation of HEPATOCYTES and ADIPOCYTES.

Also Known As:

Networked: 365 relevant articles (6 outcomes, 39 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tenen, Daniel G: 23 articles (12/2010 - 01/2002)
2.	Koeffler, H Phillip: 11 articles (08/2012 - 02/2002)
3.	Zhang, Pu: 7 articles (12/2009 - 06/2002)
4.	Calabretta, Bruno: 7 articles (09/2008 - 01/2002)
5.	Behre, G: 6 articles (11/2017 - 03/2001)
6.	Tenen, D G: 6 articles (11/2017 - 03/2001)
7.	Gery, Sigal: 6 articles (08/2012 - 12/2003)
8.	Behre, Gerhard: 6 articles (12/2010 - 07/2002)
9.	Nerlov, Claus: 6 articles (11/2009 - 11/2003)
10.	Friedman, Alan D: 6 articles (05/2009 - 06/2002)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/01/2011 - "Loss of function mutations in CCAAT/enhancer binding protein alpha (CEBPA) have been identified in acute myeloid leukemia (AML) and bi-allelic (double) CEBPA mutations are associated with improved prognosis in cases of cytogenetically normal-AML. " 07/11/2014 - "CCAAT/enhancer-binding protein alpha (CEBPA) mutations are a favorable prognostic factor in adult acute myeloid leukemia (AML) patients; however, few studies have examined their significance in pediatric AML patients. " 08/01/2010 - "In order to evaluate the incidence of CCAAT/enhancer binding protein alpha (cebpa) gene mutation in patients with acute myeloid leukemia (AML), 22 AML patients with normal karyotype (NK-AML) were enrolled in this study, including de novo AML and relapsed AML. " 11/01/2022 - "Mutations of CCAAT/enhancer-binding protein alpha (CEBPAmu) are found in 10% to 15% of de novo acute myeloid leukemia (AML) cases. " 12/01/2016 - "Mutations of the CCAAT/enhancer binding protein alpha (CEBPA) gene have been associated with a favorable outcome in patients with acute myeloid leukemia (AML), especially in those with a normal cytogenetics. "
2.	Leukemia 08/15/2006 - "Moreover, activation of C/EBPalpha eradicated leukemia in 4 of 10 and in 6 of 7 mice injected with STI571-sensitive or -resistant 32D-BCR/ABL cells, respectively. " 01/01/2019 - "CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice." 11/01/2017 - "Myeloid master regulator CCAAT enhancer-binding protein alpha (C/EBPα) is deregulated by multiple mechanisms in leukemia. " 02/01/2017 - "Polymerase chain reaction (PCR) and reverse transcription polymerase chain reaction (RT-PCR) of selected genes from the peripheral blood demonstrated a mixed lineage leukemia (MLL) partial tandem duplication (PTD) and sequence variant in CCAAT/enhancer binding protein alpha (CEBPA). " 01/13/2011 - "Differential effects of sumoylation on the activities of CCAAT enhancer binding protein alpha (C/EBPα) p42 versus p30 may contribute in part, to aberrant C/EBPα activity in acute leukemias."
3.	Insulin Resistance 06/01/2019 - "However, it did not affect expression of CCAAT/enhancer-binding protein alpha related with acquisition of insulin sensitivity. " 02/01/2006 - "We propose that oxidative stress induces adipocyte insulin resistance partially by affecting the expression of C/EBPalpha and delta, resulting in altered C/EBP-dimer composition potentially occupying the GLUT4 promoter." 07/06/2001 - "Thus, both C/EBPalpha and Pit-1 were required for high basal transcription while insulin sensitivity required Elk-1." 01/05/2001 - "Importantly, it has been demonstrated that several adipocyte cell lines that fail to express C/EBP alpha exhibit reduced insulin sensitivity, despite an apparent adipogenic phenotype. " 02/01/1999 - "Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity."
4.	Myocarditis (Carditis) 10/13/2008 - "Cardiac adiponectin mRNA was significantly higher in Can-early and in Can-late than in Vehicle on days 4 and 7. Cardiac C/EBPalpha in Can-early and Can-early groups was significantly increased on day 4. Myocardial NF-kappaB and TNF-alpha mRNA in Can-early and Can-late groups were significantly reduced on day 7. Candesartan treatment improved myocardial injury in obese mice with acute viral myocarditis and induced expression of cardiac adiponectin with the induction of C/EBPalpha as well as the reduction of cardiac NF-kappaB and TNF-alpha."
5.	Neoplasms (Cancer) 01/15/2002 - "Immunohistochemical study of primary tumor specimens showed undetectable or low expression of C/EBPalpha in 23 of 53 specimens. " 10/25/2017 - "In an effort to identify molecular mediators responsible for expansion and the tumor-promoting function of MDSCs, we discovered CCAAT/enhancer binding protein alpha (C/EBPα) expression was significantly reduced in MDSCs from tumor-bearing mice compared to non-tumor-bearing hosts. " 01/01/2013 - "Finally, recurrent SIP produced significantly larger amounts of C/EBP-alpha than non- recurrent tumors. " 08/01/2010 - "C/EBP alpha has a crucial role in inducing terminal differentiation and is an established tumor suppressor gene in several cancer models. " 08/01/2010 - "C/EBPalpha (cebpa) is a putative tumor suppressor. "

Related Drugs and Biologics

1.	Messenger RNA (mRNA)
2.	Adiponectin
3.	Proteins (Proteins, Gene)
4.	PPAR gamma
5.	NF-kappa B (NF-kB)
6.	Nucleophosmin
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
8.	Fatty Acid Synthases (Fatty Acid Synthase)
9.	Sterol Esterase (Hormone-Sensitive Lipase)
10.	Mitogen-Activated Protein Kinase Kinases (MEKs)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Cell Transplantation
4.	Caloric Restriction
5.	Protein-Restricted Diet (Diet, Protein Restricted)